Novocure Ltd (NVCR) — 8-K Filings

8-K Filings (18)

• NovoCure Files 8-K: Regulation FD Disclosure Issued — Mar 26, 2026
  NovoCure Ltd filed an 8-K on March 26, 2026, under Item 7.01, Regulation FD Disclosure, indicating a significant announcement or event that the company wants to
• NovoCure Files 8-K: Officer Changes & Financials — Dec 1, 2025 Risk: low
  NovoCure Limited filed an 8-K on November 24, 2025, reporting changes in directors or officers, Regulation FD disclosures, and financial statements. The filing
• NovoCure Files 8-K: Corporate Updates and Financials — Sep 15, 2025 Risk: low
  NovoCure Limited filed an 8-K on September 15, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The filing details the company'
• NovoCure Ltd Files 8-K with Corporate Updates — Aug 28, 2025 Risk: low
  NovoCure Ltd. filed an 8-K on August 28, 2025, reporting information under Regulation FD and including financial statements and exhibits. The filing details the
• NovoCure Ltd Files 8-K on Officer/Director Changes & Shareholder Votes — Jun 6, 2025 Risk: medium
  NovoCure Limited filed an 8-K on June 6, 2025, reporting events as of June 4, 2025. The filing covers the departure of directors or certain officers, election o
• NovoCure Files 8-K for May 2025 — Jun 2, 2025 Risk: low
  NovoCure Limited filed an 8-K on May 31, 2025, reporting under Regulation FD and including financial statements and exhibits. The filing details the company's p
• NovoCure Files 8-K for Financials and Exhibits — Apr 22, 2025 Risk: low
  NovoCure Limited filed an 8-K on April 22, 2025, reporting on its financial statements and exhibits. The filing does not contain specific financial figures or m
• NovoCure Files 8-K on Financials — Jan 13, 2025 Risk: low
  NovoCure Limited filed an 8-K on January 13, 2025, reporting on its financial condition and results of operations. The filing includes financial statements and
• NovoCure Files 8-K with Corporate Updates — Dec 2, 2024 Risk: low
  NovoCure Limited filed an 8-K on December 2, 2024, reporting under Regulation FD and including financial statements and exhibits. The filing details the company
• NovoCure Ltd Files 8-K with Corporate Details — Oct 15, 2024 Risk: low
  NovoCure Limited filed an 8-K on October 15, 2024, reporting under Regulation FD and including financial statements and exhibits. The filing details the company
• NovoCure Announces Leadership Changes — Sep 3, 2024 Risk: medium
  NovoCure Ltd. announced on August 30, 2024, a significant leadership transition. Dr. William F. Doyle will step down as Executive Chairman and Director, effecti
• NovoCure Ltd. Announces Board Changes and Filings — Jun 10, 2024 Risk: medium
  NovoCure Ltd. announced on June 5, 2024, a series of significant corporate actions. These include the departure of two directors, Dr. William F. Weldon and Mr.
• NovoCure Files 8-K: Regulation FD & Exhibits — May 20, 2024 Risk: low
  NovoCure Ltd. filed an 8-K on May 20, 2024, to report on a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain specific
• NovoCure Files 8-K for Reg FD and Financials — Mar 27, 2024 Risk: low
  NovoCure Limited filed an 8-K on March 27, 2024, to report on Regulation FD disclosures and financial statements. The filing details the company's principal exe
• NovoCure Files 8-K: Routine Corporate Update, Non-EGC Status Confirmed — Jan 18, 2024
  NovoCure Ltd. filed an 8-K on January 18, 2024, primarily to disclose general corporate information and confirm its status as a non-emerging growth company. The
• NovoCure Confirms Nasdaq Listing for Ordinary Shares — Jan 9, 2024
  NovoCure Ltd. filed an 8-K on January 9, 2024, to report that its Ordinary Shares, with no par value, are registered for trading on The Nasdaq Stock Market LLC
• NovoCure Files 8-K on Financial Condition & Operations — Jan 8, 2024
  NovoCure Ltd. filed an 8-K on January 8, 2024, indicating a current report pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934. The filing sp
• NovoCure Reports Executive Changes & Compensation on Jan 4 — Jan 4, 2024
  NovoCure Ltd. filed an 8-K on January 4, 2024, to report the departure of directors or certain officers, election of directors, appointment of certain officers,

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX